Recently launched trial investigates anecortave acetate for preventing AMD progression to exudative disease

Article

Enrollment has recently begun in the anecortave acetate risk reduction(AART) study that is designed to evaluate the efficacy of that angiostaticsteroid for reducing the risk of progression from dry to exudative age-relatedmacular degeneration (AMD), said Jason S. Slakter, MD.

Related Videos
This series features 1 KOL.
This series features 1 KOL.
This series features 1 KOL.
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
© 2024 MJH Life Sciences

All rights reserved.